A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the pharmacokinetic (what the body does to
the drug) parameters of telaprevir are altered in patients with moderate hepatic impairment,
compared to the pharmacokinetic parameters in patients with normal liver function, and
measure the relative unbound plasma concentrations of telaprevir.